MX2020003943A - Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. - Google Patents

Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.

Info

Publication number
MX2020003943A
MX2020003943A MX2020003943A MX2020003943A MX2020003943A MX 2020003943 A MX2020003943 A MX 2020003943A MX 2020003943 A MX2020003943 A MX 2020003943A MX 2020003943 A MX2020003943 A MX 2020003943A MX 2020003943 A MX2020003943 A MX 2020003943A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
same
cancer treatment
msln antibody
msln
Prior art date
Application number
MX2020003943A
Other languages
English (en)
Inventor
Dong Sik Kim
Ki Su Kim
Jun Hong Jeong
Yang Mi Lim
Yong Yea Park
Hyung Kwon Lim
Jong Wha Won
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2020003943A publication Critical patent/MX2020003943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-MSLN y a una composición farmacéutica para el tratamiento del cáncer que comprende el mismo. El anticuerpo anti-MSLN de acuerdo con la presente invención tiene una alta afinidad y especificidad por MSLN y, por lo tanto, puede usarse eficazmente en la prevención o el tratamiento del cáncer.
MX2020003943A 2017-10-20 2018-10-22 Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. MX2020003943A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136565A KR101966362B1 (ko) 2017-10-20 2017-10-20 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
PCT/KR2018/012493 WO2019078698A2 (ko) 2017-10-20 2018-10-22 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2020003943A true MX2020003943A (es) 2020-08-13

Family

ID=66103738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003943A MX2020003943A (es) 2017-10-20 2018-10-22 Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.

Country Status (14)

Country Link
US (1) US11401343B2 (es)
EP (1) EP3699199A4 (es)
JP (1) JP6978598B2 (es)
KR (1) KR101966362B1 (es)
CN (1) CN111247173B (es)
AU (1) AU2018351417B2 (es)
BR (1) BR112020007739A2 (es)
CA (1) CA3077009C (es)
EA (1) EA202090945A1 (es)
IL (1) IL274008A (es)
MX (1) MX2020003943A (es)
MY (1) MY194272A (es)
SG (1) SG11202003278RA (es)
WO (1) WO2019078698A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019439345A1 (en) * 2019-03-29 2021-11-18 Green Cross Corporation Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof
WO2022242703A1 (zh) * 2021-05-19 2022-11-24 江苏先声药业有限公司 抗msln抗体及其应用
WO2023131276A1 (zh) * 2022-01-06 2023-07-13 原启生物科技(上海)有限责任公司 靶向msln的抗原结合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
RS53760B1 (en) * 2007-10-01 2015-06-30 Bristol-Myers Squibb Company HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9416190B2 (en) * 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
NZ740855A (en) 2015-08-21 2022-04-29 Crage Medical Co Ltd Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
KR101782487B1 (ko) * 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
MY194272A (en) 2022-11-25
AU2018351417A1 (en) 2020-05-28
WO2019078698A2 (ko) 2019-04-25
EP3699199A4 (en) 2021-06-30
CN111247173A (zh) 2020-06-05
IL274008A (en) 2020-05-31
AU2018351417B2 (en) 2021-12-23
CN111247173B (zh) 2024-03-29
CA3077009C (en) 2023-05-16
WO2019078698A3 (ko) 2019-07-04
JP2021507678A (ja) 2021-02-25
US20200262928A1 (en) 2020-08-20
SG11202003278RA (en) 2020-05-28
US11401343B2 (en) 2022-08-02
JP6978598B2 (ja) 2021-12-08
KR101966362B1 (ko) 2019-04-05
EA202090945A1 (ru) 2020-07-14
CA3077009A1 (en) 2019-04-25
EP3699199A2 (en) 2020-08-26
BR112020007739A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2015016627A (es) Vacuna para la malaria.
MX2020003943A (es) Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
ECSP20082339A (es) Moduladores de la expresión de apol1
CL2021001246A1 (es) Moduladores de expresión irf5.
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2020003947A (es) Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CO2020003134A2 (es) Moduladores de la expresión de enac
UY38472A (es) Moduladores de la expresión de foxp3
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.